Why European IVD Distributors Have a Distinct Pre-Stocking Verification Logic
European IVD distributors follow a different pre-stocking verification logic from typical commercial distributors because the European market is regulated under the EU In Vitro Diagnostic Regulation 2017/746 (IVDR), and the IVDR imposes specific requirements on the CE-IVD marking, the classification of the device, the clinical performance data, the post-market surveillance, and the EU Authorized Representative designation. A respiratory combo test that passes the verification logic for the US market may not pass the European verification logic because the IVDR requirements are more stringent than the US FDA requirements for several aspects of the IVD lifecycle. The verification logic typically covers the CE-IVD marking verification, the classification under IVDR Annex VIII, the clinical performance validation, the lot-to-lot consistency, the supply chain reliability, the post-market surveillance program, the packaging customization, and the commercial terms.
For European distributors evaluating respiratory combo test suppliers, the COVID-19 test product range provides the candidate products for the stocking program, and the COVID-19 rapid test kit is the standalone COVID antigen configuration. The Flu A/B + COVID-19 combo test cassette is the dual-pathogen configuration, the Flu A/B + COVID-19 + RSV combo test is the triple-pathogen reference configuration, and the Flu A/B + COVID-19 + hMPV + RSV combo test provides the broader respiratory pathogen coverage option. The Flu A/B + COVID-19 + RSV product listing summarizes the combo test range for distributor sourcing reference.
Verification Point 1: CE-IVD Marking Under IVDR 2017/746
The CE-IVD marking is the first verification point because the CE-IVD mark is the legal requirement for placing an IVD on the European market under IVDR 2017/746. The IVDR replaced the older IVD Directive 98/79/EC and has applied since 26 May 2022, and the IVDR imposes substantially more stringent requirements on the conformity assessment route, the Notified Body involvement, and the post-market surveillance obligations. A respiratory combo test that carries only the legacy IVDD CE marking is not legally compliant for placement on the European market after the IVDR transition deadlines, and the legacy IVDD CE marking does not grant continued access to the European market for devices that require Notified Body involvement under IVDR.
For verification, the distributor should request the CE-IVD certificate from the supplier, and the distributor should verify the certificate against the European Commission NANDO database. The NANDO database lists the IVDR-designated Notified Bodies, and the certificate must reference an IVDR-designated Notified Body for the device’s classification under Annex VIII. The CE-IVD certificate should specify the device name, the device classification, the Notified Body number, and the certificate validity period, and the distributor should confirm that the certificate covers the specific product configuration being stocked. A supplier that cannot provide the CE-IVD certificate or that has a certificate issued by a non-IVDR-designated Notified Body is operating below the European regulatory standard, and the supplier should be replaced with a supplier that maintains the IVDR CE-IVD certificate.
For distributors that source from manufacturers outside the European Union, the supplier must also designate an EU Authorized Representative per IVDR Article 11, and the EU Authorized Representative must be registered in the EUDAMED database. The distributor should request the EU Authorized Representative designation letter, and the distributor should verify the EU Authorized Representative registration in the EUDAMED database. A supplier that has not designated an EU Authorized Representative or that has an EU Authorized Representative that is not registered in EUDAMED is operating below the European regulatory standard, and the supplier should be replaced with a supplier that maintains the EU Authorized Representative designation.
Verification Point 2: IVDR Annex VIII Classification
The classification of a respiratory combo test depends on its intended use and the target user. A professional-use Flu A/B + COVID-19 + RSV antigen combo test typically falls under Class B in IVDR Annex VIII Rule 3 (detection of infectious agents that are not on the high-risk list), which requires Notified Body involvement for the CE marking. A self-test configuration intended for lay users typically falls under Class C in IVDR Annex VIII Rule 4 (self-testing devices for serious conditions), which requires additional Notified Body scrutiny and typically includes consultation with a competent authority. Distributors should verify the classification of the specific product configuration being stocked, because the classification drives the conformity assessment route and the post-market surveillance obligations.
For verification, the distributor should request the supplier’s IVDR classification rationale, and the distributor should verify the rationale against the IVDR Annex VIII rules and the MDCG guidance documents. The classification rationale should specify the intended use, the target user, the analyte, and the analyte’s risk category, and the rationale should be consistent with the CE-IVD certificate’s classification scope. A supplier that cannot provide the classification rationale or that has an inconsistent classification across the technical documentation is operating below the European regulatory standard, and the supplier should be asked for the classification clarification before the stocking commitment is made.
For distributors that stock multiple product configurations (for example, both a professional-use configuration and a self-test configuration), the distributor should verify the classification for each configuration separately, because the conformity assessment route and the post-market surveillance obligations differ by classification. The professional-use Class B configuration and the self-test Class C configuration require different Notified Body scrutiny, and the distributor should ensure that the CE-IVD certificate covers the specific configuration being stocked. A supplier that provides a CE-IVD certificate that does not cover the specific configuration being stocked is operating below the European regulatory standard for the configuration mismatch, and the supplier should be replaced with a supplier that maintains the configuration-specific CE-IVD certificate.
Verification Point 3: Clinical Performance Validation
The clinical performance validation is the third verification point because the IVDR requires the manufacturer to demonstrate the clinical performance of the device for the intended use. For a respiratory combo test, the clinical performance data should demonstrate high sensitivity for each pathogen target (Flu A, Flu B, COVID-19, RSV) and high specificity against the co-circulating respiratory pathogens. The clinical performance data should be evaluated against a CE-marked reference PCR test as the comparator, and the study population should include European or temperate-climate populations because the pathogen prevalence varies by geographic region.
For verification, the distributor should request the clinical study report for the specific product configuration being stocked, and the distributor should verify the sample size, the reference method, and the discordant sample resolution procedure. The clinical study report should specify the performance values for each pathogen target separately, and the report should specify the co-infection performance data for the combo test configuration. A supplier that provides a clinical study report that does not separate the pathogen-specific performance data is operating below the IVDR clinical performance expectation, and the supplier should be asked for the analyte-specific performance breakdown before the stocking commitment is made.
For distributors that stock respiratory combo tests for the European flu season, the distributor should also request the supplier’s seasonal performance data because the pathogen prevalence varies across the flu season peak window. The seasonal performance data should demonstrate that the test maintains performance across the seasonal variation in viral load, and the data should be referenced against the supplier’s regulatory submission. A supplier that cannot provide the seasonal performance data or that has a clinical study that does not cover the European temperate-climate population is operating below the European stocking standard, and the supplier should be asked for the European seasonal performance data or the equivalent temperate-climate data before the stocking commitment is made.
Verification Point 4: Lot-to-Lot Consistency
The lot-to-lot consistency is the fourth verification point because the IVDR requires the manufacturer to demonstrate that the device performance is consistent across production lots. For a respiratory combo test, the lot-to-lot consistency data should include the coefficient of variation (CV) of the test line intensity for at least 3 to 5 consecutive production lots (one for each pathogen target), the inter-lot agreement on positive and negative controls for each pathogen, and the inter-lot stability data from accelerated aging studies. The lot-to-lot consistency data should demonstrate that the test performance is consistent across production lots and that the inter-lot agreement meets the supplier’s regulatory submission.
For verification, the distributor should request the lot-to-lot consistency data from the supplier, and the distributor should verify that the data covers at least 3 consecutive production lots for each pathogen target. The distributor should also verify that the inter-lot agreement meets the supplier’s regulatory submission, and the distributor should request the inter-lot stability data from accelerated aging studies. A supplier that cannot provide the lot-to-lot consistency data or that has a gap in the inter-lot stability data is operating below the IVDR lot-to-lot consistency expectation, and the supplier should be asked for the data completion before the stocking commitment is made.
For distributors that source from manufacturers with high-volume production (which is typical for the European flu season demand), the distributor should also request the supplier’s high-volume lot-to-lot consistency data because the production scale can affect the lot-to-lot consistency. The high-volume lot-to-lot consistency data should demonstrate that the test performance remains consistent at the higher production volumes, and the data should be referenced against the supplier’s regulatory submission. A supplier that cannot provide the high-volume lot-to-lot consistency data or that has a documented inconsistency at the higher production volumes is operating below the European stocking standard for high-volume deployment, and the supplier should be replaced with a supplier that maintains the high-volume consistency.
Verification Point 5: Supply Chain Reliability for European Flu Season Demand
The supply chain reliability for European flu season demand is the fifth verification point because the European flu season typically creates a surge in demand for respiratory combo tests, and the supplier’s ability to meet the demand surge is critical to the distributor’s stocking program. A respiratory combo test supplier should provide supply chain documentation that includes the manufacturing lead time per lot, the typical shipment duration to the European destination port, the cold chain requirements (most respiratory combo tests require only 4 to 30 degrees Celsius storage and do not require refrigerated shipping), the shelf life at the recommended storage temperature (24 months for respiratory combo RDTs at the recommended storage condition), the customs documentation support for European destination countries (EU import documentation, CE-IVD certificate copy, country of origin certificate), and the EU Authorized Representative designation (mandatory under IVDR for non-EU manufacturers).
For verification, the distributor should request the supplier’s supply chain documentation, and the distributor should verify that the documentation covers the European destination country’s specific requirements. The distributor should also request the supplier’s historical on-time delivery rate for the European destination, and the distributor should verify the historical rate against the supplier’s post-market surveillance report. A supplier that cannot provide the supply chain documentation or that has a poor historical on-time delivery rate is operating below the European stocking standard, and the supplier should be replaced with a supplier that maintains the supply chain reliability.
For distributors that stock respiratory combo tests for the European flu season, the distributor should also request the supplier’s contingency plan for the demand surge because the European flu season typically creates a demand spike that can outpace the supplier’s standard production capacity. The contingency plan should include the alternative production lines, the alternative raw material sources, and the alternative shipping routes. A supplier that cannot provide the contingency plan or that has a documented history of supply disruption during the European flu season is operating below the European stocking standard for the seasonal demand, and the supplier should be replaced with a supplier that maintains the contingency plan.
Verification Point 6: Packaging Customization and Private Label Compatibility
The packaging customization and private label compatibility is the sixth verification point because European distributors typically stock respiratory combo tests under their own private label, and the packaging customization capability is critical to the distributor’s branding and market positioning. A respiratory combo test supplier should support the packaging customization options including the kit box printing with the distributor’s brand, the cassette foil pouch printing with the distributor’s brand, the instruction for use (IFU) translation into the European destination languages, and the label compliance with the IVDR labeling requirements (UDI, CE-IVD marking, EU Authorized Representative address).
For verification, the distributor should request the supplier’s packaging customization options, the customization lead time, the customization cost, and the customization minimum order quantity. For suppliers offering OEM customization, the minimum order quantity is 50,000 pieces, and the standard catalog minimum order quantity is 5,000 pieces per the supplier’s product policy. The customization lead time is typically negotiated per project, and the customization cost should be transparent in the supplier’s commercial proposal. A supplier that cannot provide the packaging customization or that has an unreasonably high customization cost is operating below the European distributor service standard, and the supplier should be replaced with a supplier that supports the customization at the distributor’s terms.
For distributors that stock respiratory combo tests for multiple European destination countries, the distributor should also request the IFU translation capability, and the IFU should be translated into each destination country’s official language(s). The IFU translation should comply with the IVDR labeling requirements and should be reviewed by a qualified regulatory translator. A supplier that cannot provide the IFU translation or that has a translation that does not comply with the IVDR labeling requirements is operating below the European distributor service standard for the multi-country deployment, and the supplier should be replaced with a supplier that maintains the IFU translation capability.
Verification Point 7: Commercial Terms and Total Cost of Ownership
The commercial terms and total cost of ownership is the seventh verification point because European distributors typically operate on a defined commercial margin structure, and the supplier’s commercial terms need to align with the distributor’s margin structure. A respiratory combo test supplier should provide commercial terms that include the per-unit price, the volume discount tier, the payment terms, the shipping cost (CIF or FOB depending on the distributor’s preference), the customs clearance cost, and the local distribution cost. The supplier should also provide the total cost of ownership that includes the per-test cost, the lot-to-lot QC cost (if any), the post-market surveillance cost (if any), and the field performance monitoring cost (if any).
For verification, the distributor should request the supplier’s commercial terms, and the distributor should verify that the commercial terms align with the distributor’s margin structure. The distributor should also request the supplier’s payment terms, and the payment terms should be acceptable to the distributor’s cash flow cycle. A supplier that provides only the per-unit price without the volume discount tier or the total cost of ownership breakdown is operating below the European distributor commercial standard, and the supplier should be asked for the complete commercial terms before the stocking commitment is made.
For distributors that stock respiratory combo tests for the European flu season, the distributor should also request the supplier’s historical pricing stability, and the supplier should not have a documented history of mid-contract price increases during the European flu season peak window. The pricing stability is the basis for the distributor’s commercial planning, and the pricing stability should be documented in the supply contract. A supplier that has a documented history of mid-contract price increases during the European flu season is operating below the European distributor commercial standard for the seasonal stocking, and the supplier should be replaced with a supplier that maintains the pricing stability.
Beyond the Seven Verification Points: European Flu Season Demand Forecasting
Beyond the seven verification points, the European IVD distributor should also conduct a demand forecasting analysis for the respiratory combo tests for the European flu season. In our work with European distributors across the past several flu seasons, we have seen that the demand forecasting is the most underestimated verification step, and we recommend that distributors allocate at least 2 to 3 weeks for the demand forecast review before the stocking commitment is made. The demand forecasting analysis should include the historical flu season demand for the European destination country, the projected flu season demand for the upcoming season, the competitor product launch calendar, and the public health emergency reserve requirement. We typically share our own flu season demand pattern data with our European distributor partners, and our team works with the distributor to align the stocking volume with the projected demand so that overstocking and stockout situations are both minimized. The demand forecasting analysis is the basis for the distributor’s stocking volume, and we recommend that the demand forecasting be referenced against the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO) influenza surveillance reports.
For demand forecasting, the distributor should also evaluate the supplier’s responsiveness to the demand surge because the European flu season demand can change rapidly based on the pathogen prevalence. The supplier’s responsiveness should be documented in the supply contract, and the responsiveness should include the communication channel, the response time, the production capacity allocation, and the shipment scheduling. A supplier that has a documented history of slow responsiveness to the demand surge is operating below the European stocking standard for the seasonal demand, and the supplier should be replaced with a supplier that maintains the responsiveness.
For distributors that source respiratory combo tests from China-based manufacturers (which is typical for the European IVD distributor sourcing program), the distributor should also evaluate the China export documentation support, including the China customs declaration, the China origin certificate, and the China export inspection certificate. The China export documentation is the basis for the European customs clearance, and the documentation should be available from the supplier before the shipment. A supplier that cannot provide the China export documentation or that has a documented history of China export documentation errors is operating below the European stocking standard for the China-sourced supply, and the supplier should be replaced with a supplier that maintains the export documentation support.
Frequently Asked Questions from European IVD Distributors
What CE-IVD marking should a respiratory combo test have for European distributors under IVDR?
A respiratory combo test sold into the European market must comply with the EU In Vitro Diagnostic Regulation 2017/746 (IVDR), which replaced the older IVD Directive 98/79/EC and applies since 26 May 2022. Under IVDR, the test must have a CE-IVD marking issued by a Notified Body for the device’s classification under Annex VIII, and the CE-IVD certificate must be issued by an IVDR-designated Notified Body listed on the European Commission NANDO database. The classification of a respiratory combo test depends on its intended use and the target user: a professional-use Flu A/B + COVID-19 + RSV antigen combo test typically falls under Class B in IVDR Annex VIII Rule 3, which requires Notified Body involvement for the CE marking, while a self-test configuration typically falls under Class C in IVDR Annex VIII Rule 4 and requires additional Notified Body scrutiny.
What clinical sensitivity and specificity should a respiratory combo test meet for European stocking?
For European distributor stocking, the clinical sensitivity and specificity of a respiratory combo test should be evaluated against a CE-marked reference PCR test as the comparator. The clinical performance data should demonstrate high sensitivity for each pathogen target (Flu A, Flu B, COVID-19, RSV) and high specificity against the co-circulating respiratory pathogens. The clinical study report should specify the sample size, the reference method, the co-infection performance data, and the study population, with the European or temperate-climate population preferred because the pathogen prevalence varies by geographic region. The clinical study report should be current for the product configuration being stocked, and the report should be referenced against the supplier’s regulatory submission rather than treated as a fixed benchmark. Procurement officers should verify the specific performance values against the relevant MDCG guidance documents and the supplier’s regulatory submission.
What lot-to-lot consistency data should a respiratory combo test supplier provide?
A respiratory combo test supplier should provide lot-to-lot consistency data that includes the coefficient of variation (CV) of the test line intensity for at least 3 to 5 consecutive production lots (one for each pathogen target), the inter-lot agreement on positive and negative controls for each pathogen, and the inter-lot stability data from accelerated aging studies. The lot-to-lot consistency data should demonstrate that the product performance is consistent across production lots, and the data should be referenced against the supplier’s regulatory submission. Distributors should treat these performance values as benchmarks to be confirmed against the supplier’s regulatory submission, and the procurement specification should explicitly state the acceptable CV and the acceptable inter-lot agreement per the supplier’s regulatory submission.
What supply chain documentation should a respiratory combo test supplier provide for European distributors?
A respiratory combo test supplier should provide supply chain documentation that includes the manufacturing lead time per lot, the typical shipment duration to the European destination port, the cold chain requirements (most respiratory combo tests require only 4 to 30 degrees Celsius storage and do not require refrigerated shipping), the shelf life at the recommended storage temperature (24 months for respiratory combo RDTs at the recommended storage condition), the customs documentation support for European destination countries (EU import documentation, CE-IVD certificate copy, country of origin certificate), and the EU Authorized Representative designation (mandatory under IVDR for non-EU manufacturers). Distributors should request the supplier’s historical on-time delivery rate for European destination shipments and should request the supplier’s contingency plan for shipment delays during the European flu season peak window. For suppliers offering OEM customization, the minimum order quantity is 50,000 pieces, and the standard catalog minimum order quantity is 5,000 pieces per the supplier’s product policy.
What post-market surveillance should a respiratory combo test supplier maintain for European distribution under IVDR?
Under IVDR, a respiratory combo test manufacturer must maintain a post-market surveillance system that includes a post-market surveillance plan per IVDR Article 79, a post-market performance follow-up (PMPF) plan per IVDR Article 80, a periodic safety update report (PSUR) per IVDR Article 81 for Class C and above devices, and a vigilance reporting procedure per IVDR Article 82 to 92. The post-market surveillance documentation should be available to the EU Authorized Representative and should be updated at least annually. The supplier should also maintain a designated contact person for the post-market surveillance reports, and the contact should respond to vigilance issues within the IVDR-mandated reporting timelines (per IVDR Article 83, serious incidents must be reported to the competent authority within a defined calendar day window, and serious public health threats must be reported within an even shorter window).
For European IVD distributors evaluating respiratory combo test suppliers for the upcoming flu season demand, our team can provide the CE-IVD certificate, the IVDR Annex VIII classification rationale, the clinical study report, the lot-to-lot consistency data, the supply chain documentation, the IVDR post-market surveillance plan, and the packaging customization options for our respiratory combo test range. Reach out through our contact page with your expected annual volume, target European destination countries, and preferred packaging customization option to receive the stocking prequalification package promptly. The Testsealabs about us page summarizes the company’s IVDR compliance posture and the regulatory approvals for the European market. Standard catalog minimum order quantity is 5,000 pieces; OEM customization minimum order quantity is 50,000 pieces.
Written by Angela Qin — International Sales Director at Hangzhou Testsea Biotechnology Co., Ltd. (Testsealabs), with 10+ years of experience in the in vitro diagnostic (IVD) industry. Founded in 2015 with the pursuit “serving society, health world,” Testsealabs specializes in the R&D, production, and sales of rapid diagnostic products, including tests for coronavirus disease, cardiovascular diseases, inflammation, tumor markers, infectious diseases, drug abuse, and pregnancy. Leveraging proprietary platforms (immunological detection, molecular biology, protein chip, and biological raw materials), Angela helps global distributors, hospitals, and public health institutions source reliable, high-quality diagnostic solutions from China—backed by strict quality control and a customer-first philosophy. Testsealabs holds both ISO 13485 and MDSAP certifications covering the QMS requirements of FDA, Health Canada, TGA, ANVISA, and PMDA. Testsealabs’ products are widely used in rapid diagnosis, treatment monitoring, maternal and child healthcare, drug and alcohol testing, and have been sold to over 100 countries worldwide. Connect: Facebook
Post time: Jul-17-2026